Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument
Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument
复制标题
DOI：
10.1200/jco.1997.15.3.974
复制
发表时间：
1997-03-01
影响因子：
45.3
通讯作者：
Shiomoto, G
中科院分区：
文献类型：
--
作者：
Brady, MJ;Cella, DF;Shiomoto, G
目的：这是第一份关于癌症治疗功能评估-乳腺（FACT-B）验证的报告，FACT-B是一种44项自我报告工具，旨在测量乳腺癌患者的多维生活质量（QL）。FACT-B由FACT-General（FACT-G）和乳腺癌子量表（BCS）组成，后者使用乳腺癌QL特定项目补充了一般量表。FACT-B的开发重点是患者的价值和简洁性，并提供九种语言。方法和结果：本报告使用了两个验证样本。在2个月内对第一组（n = 47）进行了两次测试，以评估对变化的敏感性，证明FACT-B总分、身体健康（PWB）子量表、功能健康（FWB）子量表和BCS对体能状态评分（PSR）变化具有显著敏感性。在FACT-B总评分、PWB、FWB和情感幸福感（EWB）中记录对QL变化的敏感性（通过癌症功能性生活指数（FLIC）测量）。从更大的样本（n = 295）中获得了额外的有效性和可靠性数据。FACT-B总分的α系数（内部一致性）较高（α = 0.90），子量表α系数范围为0.63 - 0.86。证据支持重测信度，以及收敛，发散，和已知的组validity.Conclusion：FACT-B是适当的肿瘤学临床试验中使用，以及在临床实践中。它证明了易于管理，简洁，可靠性，有效性和对变化的敏感性。(C)1997年，美国临床肿瘤学会。
Purpose: This is the first published report on the validation of the Functional Assessment of Cancer Therapy-Breast (FACT-B), a 44-item self-report instrument designed to measure multidimensional quality of life (QL) in patients with breast cancer. The FACT-B consists of the FACT-General (FACT-G) plus the Breast Cancer Subscale (BCS), which complements the general scale with items specific to QL in breast cancer. The FACT-B was developed with an emphasis on patients' values and brevity and is available in nine languages.Methods and Results: Two validation samples were used for this report. The first (n = 47) was tested twice over a 2-month period to assess sensitivity to change, Significant sensitivity to change in performance status rating (PSR) was demonstrated for the FACT-B total score, the Physical Well-Being (PWB) subscale, the Functional Well-Being (FWB) subscale, and the BCS. Sensitivity to change in QL as measured by the Functional Living Index-Cancer (FLIC) was documented in the FACT-B total score, PWB, FWB, and Emotional Well-Being (EWB). Additional validity and reliability data were obtained from a larger sample (n = 295). The alpha coefficient (internal consistency) for the FACT-B total score was high (alpha = .90), with subscale alpha coefficients ranging from .63 to .86. Evidence supported test-retest reliability, as well as convergent, divergent, and known groups validity.Conclusion: The FACT-B is appropriate for use in oncology clinical trials, as well as in clinical practice. It demonstrates ease of administration, brevity, reliability, validity, and sensitivity to change. (C) 1997 by American Society of Clinical Oncology.